Epidemiological, clinical, and therapeutic characteristics of Behçet's disease: a monocentric study in Tunisia.
Behçet's disease
prognosis
treatment
vasculitis
Journal
The Pan African medical journal
ISSN: 1937-8688
Titre abrégé: Pan Afr Med J
Pays: Uganda
ID NLM: 101517926
Informations de publication
Date de publication:
2021
2021
Historique:
received:
16
05
2019
accepted:
23
05
2020
entrez:
4
11
2021
pubmed:
5
11
2021
medline:
10
11
2021
Statut:
epublish
Résumé
to describe the epidemiological, clinical, therapeutic and evolving characteristics of Behçet´s disease and identify prognostic factors. we have realized a retrospective, single-center study, conducted over a period of 26 years and including 130 patients presenting Behçet´s disease and hospitalized in an Internal Medicine Department. the mean age of the Behçet´s disease at onset was 30.3 ±8.8 years and that at diagnosis was 34.6 ±9.4 years. The sex ratio (male/female) was 2.5. The mean delay of diagnosis was 53.5 months. Oral aphthosis was constant. The frequency of the manifestations was: genital aphtosis 71.5%, pseudofolliculitis 84.6%, erythema nodosum 11.5%, positive pathergy test 50%, ocular disease 36.9%, venous thrombosis 30%, arterial disease 4.6%, joint damage 30.8%, neurological disease 19.2% and digestive disease 0.8%. The male gender was significantly associated with ocular involvement (p =0.02), venous disease (p =0.01) and occurrence of relapses (p =0.01). The mean follow up was 68.5 ± 77.3 months. The poor survival prognostic factors were male gender, ocular involvement, venous disease, cardiovascular disease, a duration of follow up ≤12 months and a diagnostic delay ≤ 24 months.
Identifiants
pubmed: 34733381
doi: 10.11604/pamj.2021.40.13.19146
pii: PAMJ-40-13
pmc: PMC8531968
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
13Informations de copyright
Copyright: Fatma Daoud et al.
Déclaration de conflit d'intérêts
The authors declare no competing interests.
Références
Arthritis Rheumatol. 2014 May;66(5):1306-14
pubmed: 24782188
Arthritis Rheum. 2008 Dec;58(12):3951-9
pubmed: 19035493
Ann Rheum Dis. 2018 Jun;77(6):808-818
pubmed: 29625968
Brain. 1999 Nov;122 ( Pt 11):2171-82
pubmed: 10545401
J Neurol. 2001 Feb;248(2):95-103
pubmed: 11284141
Clin Exp Rheumatol. 2003 Jul-Aug;21(4 Suppl 30):S19-26
pubmed: 14727454
Int J Dermatol. 2014 May;53(5):564-9
pubmed: 23967880
Rev Med Interne. 2006 Oct;27(10):742-50
pubmed: 16987570
Presse Med. 2009 May;38(5):701-9
pubmed: 19062244
Rev Med Interne. 2014 Feb;35(2):126-38
pubmed: 24438860
Lancet Neurol. 2009 Feb;8(2):192-204
pubmed: 19161910
Rheumatol Int. 2012 Jul;32(7):2063-7
pubmed: 21479883
J Eur Acad Dermatol Venereol. 2014 Mar;28(3):338-47
pubmed: 23441863
Medicine (Baltimore). 2011 Mar;90(2):125-132
pubmed: 21358436
Rev Med Interne. 2009 Dec;30 Suppl 4:S229-31
pubmed: 19913958
J Korean Med Sci. 2003 Apr;18(2):231-5
pubmed: 12692421
Presse Med. 2012 Feb;41(2):e52-62
pubmed: 21868192
Ann Rheum Dis. 2009 Oct;68(10):1528-34
pubmed: 18420940
Rev Med Interne. 2014 Feb;35(2):112-20
pubmed: 24290030
Rev Med Interne. 2014 Feb;35(2):103-11
pubmed: 24434015
Int J Rheum Dis. 2010 Oct;13(4):367-73
pubmed: 21199472
Clin Dermatol. 2013 Jul-Aug;31(4):352-361
pubmed: 23806152
Medicine (Baltimore). 2012 Jan;91(1):25-34
pubmed: 22198500
Int J Dermatol. 2003 May;42(5):346-51
pubmed: 12755969
Rev Med Interne. 2009 Dec;30 Suppl 4:S238-42
pubmed: 19854546